Experimental gene therapy found to slow Huntington’s disease progression, company says

The Amsterdam-based company announced Wednesday that patients who received a high dose of its AMT-130 therapy for Huntington’s disease saw disease progression slow by 75% after 36 months. The treatment was “generally well-tolerated,” with a “manageable” safety profile, the company said. The full st...

Redirecting to full article...